RSS Feeds
Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease
- P. P. Sfikakis, MD;
- P. H. Kaklamanis, MD;
- A. Elezoglou, MD;
- N. Katsilambros, MD;
- P. G. Theodossiadis, MD;
- S. Papaefthimiou, MD; and
- N. Markomichelakis, MD
- From Laikon Hospital, Athens University Medical School, 15452 Athens, Greece.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: In Adamantiades–Behçet disease, recurrent ocular inflammation may lead to loss of vision despite continuous immunosuppressive therapy (1-3). Preliminary evidence suggests that the anti–tumor necrosis factor (TNF) monoclonal antibody infliximab rapidly controls sight-threatening inflammation, a critical factor in avoiding chronic, irreversible retinal lesions (4, 5).
Objective: In this open, prospective study, we report on 25 patients who were treated with a single infliximab infusion at the immediate onset of a relapse. The primary outcome measure was the time to complete suppression of ocular inflammation. We also report on 15 of these patients who had experienced at least one additional relapse …
